Monoclonal Antibody Pipeline Focused on Oncology

Dedicated to changing patients’ lives.

Learn More

Better Life Through Better Science

KaloBios is developing proprietary customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with cancer.

Recent Corporate Highlights

  • Initiated Phase 2 expansion portion of clinical trial for KB004 in hematologic malignancies
  • Announced preliminary Phase 1 results in advanced hematologic malignancies with KB004 at ASH Annual Meeting

Read All

Latest News

June 17, 2015

KaloBios to Present at the JMP Securities Life Sciences Conference

May 28, 2015

KaloBios Appoints Ronald A. Martell Executive Chairman

May 11, 2015

KaloBios Reports First Quarter 2015 Financial Results


Upcoming Events

June 23, 2015

KaloBios to Present at the JMP Securities Life Sciences Conference

Ongoing Clinical Trials

Currently enrolling patients with myelofibrosis or myelodysplastic syndrome in Phase 2 expansion portion of Phase 1/2 clinical trial in hematologic malignancies.

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue